ICH Q11 Development and Manufacture of Drug Substances

E555153

ICH guideline pharmaceutical quality guideline

ICH Q11 Development and Manufacture of Drug Substances is an ICH guideline that provides principles and expectations for the development and manufacturing of chemical and biotechnological drug substances within a quality-by-design framework.

Try in SPARQL Jump to: Surface forms Disambiguation Statements Elicitation Referenced by

All labels observed (3)

Label	Occurrences
ICH Q11 Development and Manufacture of Drug Substances canonical	2
ICH Harmonised Tripartite Guideline Q11: Development and Manufacture of Drug Substances	1
ICH Q11	1

How this entity was disambiguated

This entity first appeared as the object of triple T5932397 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07

Target entity: ICH Q11 Development and Manufacture of Drug Substances
Context triple: [ICH Q8 Pharmaceutical Development, relatedTo, ICH Q11 Development and Manufacture of Drug Substances]

A. ICH Q8 Pharmaceutical Development
ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
B. ICH Q10 Pharmaceutical Quality System
ICH Q10 Pharmaceutical Quality System is an international guideline that establishes a comprehensive, lifecycle-based framework for pharmaceutical quality management to ensure consistent product quality and regulatory compliance.
C. ICH Q9 Quality Risk Management
ICH Q9 Quality Risk Management is an international guideline that provides a systematic, science- and risk-based approach to identifying, evaluating, and controlling quality risks throughout the lifecycle of pharmaceutical products.
D. Office of Pharmaceutical Quality
The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
E. Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
F. None of above. chosen
G. Unsure - the case is ambiguous/there is not enough information to decide.

NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07

Target entity: ICH Q11 Development and Manufacture of Drug Substances
Target entity description: ICH Q11 Development and Manufacture of Drug Substances is an ICH guideline that provides principles and expectations for the development and manufacturing of chemical and biotechnological drug substances within a quality-by-design framework.

A. ICH Q8 Pharmaceutical Development
ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
B. ICH Q10 Pharmaceutical Quality System
ICH Q10 Pharmaceutical Quality System is an international guideline that establishes a comprehensive, lifecycle-based framework for pharmaceutical quality management to ensure consistent product quality and regulatory compliance.
C. ICH Q9 Quality Risk Management
ICH Q9 Quality Risk Management is an international guideline that provides a systematic, science- and risk-based approach to identifying, evaluating, and controlling quality risks throughout the lifecycle of pharmaceutical products.
D. Office of Pharmaceutical Quality
The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
E. Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
F. None of above. chosen

Statements (49)

Predicate	Object
instanceOf	ICH guideline ⓘ pharmaceutical quality guideline ⓘ
addresses	control of starting materials ⓘ critical process parameters for drug substance manufacture ⓘ critical quality attributes of drug substances ⓘ design space for drug substance processes ⓘ lifecycle management of drug substance manufacturing processes ⓘ linkage of material attributes and process parameters to quality ⓘ risk management in drug substance development ⓘ selection of starting materials ⓘ
appliesTo	biological drug substances ⓘ biotechnological drug substances ⓘ chemical drug substances ⓘ
basedOnConcept	quality by design ⓘ
concerns	biotechnological/biological drug substances produced by cell culture or fermentation ⓘ small molecule drug substances ⓘ
documentType	harmonised tripartite guideline ⓘ
emphasizes	linkage between development data and control strategy ⓘ systematic approach to development ⓘ use of prior knowledge and experimental data ⓘ
focusesOn	development of drug substances ⓘ manufacture of drug substances ⓘ
fullTitle	ICH Harmonised Tripartite Guideline Q11: Development and Manufacture of Drug Substances ⓘ linked to: ICH Q11 Development and Manufacture of Drug Substances
hasAbbreviation	ICH Q11 ⓘ linked to: ICH Q11 Development and Manufacture of Drug Substances
includesGuidanceOn	description of manufacturing process development ⓘ establishment of control strategy ⓘ information to be submitted in regulatory dossiers ⓘ process validation considerations for drug substances ⓘ scale-up and technology transfer considerations ⓘ
issuedBy	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ⓘ
language	English ⓘ
objective	to facilitate more flexible regulatory approaches to drug substance manufacturing ⓘ to promote scientific understanding of drug substance processes ⓘ to support consistent product quality over the lifecycle ⓘ
providesPrinciplesFor	control strategy development ⓘ drug substance development ⓘ drug substance manufacturing process design ⓘ
regulatoryRegion	European Union ⓘ ICH regions ⓘ Japan ⓘ United States ⓘ linked to: United States of America
relatedTo	ICH Q10 Pharmaceutical Quality System ⓘ ICH Q8 Pharmaceutical Development ⓘ ICH Q9 Quality Risk Management ⓘ
supportsImplementationOf	ICH Q8 concepts for drug substances ⓘ pharmaceutical quality system for drug substances ⓘ quality risk management in development ⓘ
usedBy	pharmaceutical industry ⓘ regulatory authorities in ICH regions ⓘ

How these facts were elicited

Referenced by (4)

Full triples — surface form annotated when it differs from this entity's canonical label.

ICH Q8 Pharmaceutical Development → relatedTo → ICH Q11 Development and Manufacture of Drug Substances ⓘ

ICH Q9 Quality Risk Management → supports → ICH Q11 Development and Manufacture of Drug Substances ⓘ

ICH Q11 Development and Manufacture of Drug Substances → hasAbbreviation → ICH Q11 ⓘ

linked to: ICH Q11 Development and Manufacture of Drug Substances

ICH Q11 Development and Manufacture of Drug Substances → fullTitle → ICH Harmonised Tripartite Guideline Q11: Development and Manufacture of Drug Substances ⓘ